CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia
January 1, 2026
This is a remarkable proof-of-concept study—11 out of 11 patients with multi-refractory AIHA achieved complete remission after CD19 CART, with rapid Hb normalization and a median drug-free remission of 11.5 months. Toxicity was surprisingly manageable (mostly grade 1–2 cytokine release syndrome (CRS)), and the relapse biology pointing to BCMA+ long-lived plasma cells really sets up a rational next step with plasma cell–directed strategies.